Picard Medical, Inc. (NYSE: PMI) Investor Alert: Deadline in Lawsuit on April 13, 2026

A deadline is coming up on April 13, 2026 in the lawsuit filed for certain investors of Picard Medical, Inc. (NYSE: PMI) over alleged securities laws violations by Picard Medical, Inc.

Investors who purchased shares of Picard Medical, Inc. (NYSE: PMI) have certain options and there are strict and short deadlines running. Deadline: April 13, 2026. Picard Medical, Inc. (NYSE: PMI) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Tucson, AZ based Picard Medical, Inc., through its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. Their website details their most significant product is an artificial heart called "SynCardia TAH." Picard Medical, Inc. (NYSE: PMI) reported that its annual Total Revenue declined from $5.043 million in 2023 to $4.391 million in 2024, and that its Net Loss increased from $15.56 million in 2023 to $21.055 million in 2024.

On September 02, 2025, Picard Medical, Inc. (NYSE: PMI) announced that it closed its initial public offering of 4,250,000 shares of common stock, par value $0.0001 per share (the "Common Stock") at $4.00 per share (the "Offering").

Since then, shares of Picard Medical, Inc. (NYSE: PMI) declined to as low as $13.0 per share on February 12, 2026.

According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of purchasers of Picard Medical, Inc. (NYSE: PMI) common shares between September 2, 2025, and October 31, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between September 2, 2025, and October 31, 2025, the defendants failed to disclose to investors that Picard Medical, Inc was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals, that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign, that Picard Medical, Inc's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price, and that as a result of the foregoing, defendants' positive statements about Picard's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Picard Medical, Inc. (NYSE: PMI) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.